5일 전부터 지속되는 황달
Jaundice That Has Persisted for 5 Days
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Hepatitis B virus (HBV) reactivation associated with various therapeutic interventions is a significant cause of morbidity and mortality among patients with current or resolved HBV infection. Since no curative treatment for HBV infection is currently available, a large number of individuals in the general population are at risk for HBV reactivation. Populations vulnerable to HBV reactivation include those currently infected with HBV or those who have had past exposure to the virus. The potential consequences of HBV reactivation are particularly concerning when these populations undergo anti-cancer chemotherapy, immunosuppressive or immunomodulatory therapies for managing various malignancies, rheumatologic diseases, inflammatory bowel disease, or undergo solid-organ or hematologic stem cell transplantation. This article aims to increase awareness of HBV reactivation and to elucidate the mechanisms and risks associated with HBV reactivation in various clinical settings.
Abstract
Hepatitis B virus (HBV) reactivation associated with various therapeutic interventions is a significant cause of morbidity and mortality among patients with current or resolved HBV infection. Since no curative treatment for HBV infection is currently available, a large number of individuals in the general population are at risk for HBV reactivation. Populations vulnerable to HBV reactivation include those currently infected with HBV or those who have had past exposure to the virus. The potential consequences of HBV reactivation are particularly concerning when these populations undergo anti-cancer chemotherapy, immunosuppressive or immunomodulatory therapies for managing various malignancies, rheumatologic diseases, inflammatory bowel disease, or undergo solid-organ or hematologic stem cell transplantation. This article aims to increase awareness of HBV reactivation and to elucidate the mechanisms and risks associated with HBV reactivation in various clinical settings.
참고문헌 (16)
- Lau GK, "High hepatitis B virus(HBV)DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation", Blood, 99, pp.2324~2330 (2002)
- Seto WK, "Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma : a prospective study", J Clin Oncol, 32, pp.3736~3743 (2014)
- Seto WK, "Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation : a prospective study", Hepatology, 65, pp.1451~1461 (2017)
- Korean Association for the Study of the Liver(KASL), "KASL clinical practice guidelines for management of chronic hepatitis B", Clin Mol Hepatol, 28, pp.276~331 (2022)
- Perrillo RP, "American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy", Gastroenterology, 148, pp.221~244 (2015)
- Kim TW, "Risk of hepatitis B virus reactivation in patients with asthma or chronic obstructive pulmonary disease treated with corticosteroids", Respirology, 15, pp.1092~1097 (2010)
- Reddy KR, "American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy", Gastroenterology, 148, pp.215~219 (2015)
- Stuck AE, "Risk of infectious complications in patients taking glucocorticosteroids", Rev Infect Dis, 11, pp.954~963 (1989)
- Wong GL, "Impact of dose and duration of corticosteroid on the risk of hepatitis flare in patients with chronic hepatitis B", Liver Int, 39, pp.271~279 (2019)
- Yeo W, "Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy : a prospective study", J Med Virol, 70, pp.553~561 (2003)
- Cheng AL, "Steroid-free chemotherapy decreases risk of hepatitis B virus(HBV)reactivation in HBV-carriers with lymphoma", Hepatology, 37, pp.1320~1328 (2003)
- Hammond SP, "Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation", Biol Blood Marrow Transplant, 15, pp.1049~1059 (2009)
- Viganò M, "Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT", Bone Marrow Transplant, 46, pp.125~131 (2011)
- Guidotti LG, "Immunobiology and pathogenesis of viral hepatitis", Annu Rev Pathol, 1, pp.23~61 (2006)
- Tsutsumi Y, "Hepatitis B virus reactivation with a rituximab-containing regimen", World J Hepatol, 7, pp.2344~2351 (2015)
- Kusumoto S, "Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy", Blood, 133, pp.137~146 (2019)